The European Tinnitus Survey: a Study on Tinnitus Prevalence in 12 European Countries
Launched by MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH · May 13, 2021
Trial Information
Current as of July 08, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND AND RATIONALE Tinnitus is a common symptom of clinically heterogeneous pathologies and is defined as the conscious perception of an auditory sensation in the absence of a corresponding external stimulus. Tinnitus, in its debilitating form, negatively affects emotional health and social well-being, and can precipitate psychological distress severe enough to cause self-harm and suicidal ideations, while exerting substantial individual and societal financial burden. Therefore, it becomes crucial to implement adequate preventive measures and health interventions. According to populat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • individuals aged 18 years and above
- • individuals who are residents of the 12 selected countries
- • individuals able to understand and answer the questions of the study questionnaire in the country-specific language
- • individuals who formally accept to participate in the study
- Exclusion Criteria:
- • No specific exclusion criteria are considered
About Mario Negri Institute For Pharmacological Research
The Mario Negri Institute for Pharmacological Research is a leading Italian biomedical research organization dedicated to advancing pharmacological science and improving public health. Established in 1963, the Institute focuses on innovative research methodologies, drug development, and clinical trials aimed at understanding and treating various diseases. With a multidisciplinary team of scientists and clinicians, the Institute collaborates with national and international partners to translate research findings into clinical applications, contributing significantly to the fields of pharmacology, epidemiology, and biostatistics. Committed to excellence in research and ethical standards, the Mario Negri Institute plays a vital role in shaping the future of medical science and enhancing therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Patients applied
Trial Officials
Silvano Gallus, ScD
Principal Investigator
Istituto Di Ricerche Farmacologiche Mario Negri
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials